Hypera company profile

HYPE3 · B3 · BRL

Compare Hypera
R$21.77Change from previous close: 0.00%

Close · November 22, 2026

Company profile

Hypera has 10,564 employees and is headquartered in São Paulo, Brazil.

Doril, Buscopan, Neosaldina and Engov are among the brands most people associate with Hypera S.A., a Brazilian drugmaker whose catalogue covers painkillers and anti-inflammatories, cold and flu remedies, antihistamines, digestive products, antiseptics such as Merthiolate, herbal medicines, vitamins, supplements and skincare lines. Its activities are concentrated in Brazil, and the group also sells generics under the neo quimica name as well as sweeteners under Adocyl and Zero-cal, with the Dramin and Cepacol brands rounding out its range.

In the fiscal year ended December 2025, revenue came to BRL 7.7 billion, up 3.4% from the prior year, and net income reached BRL 1.2 billion. Founded in 1999, the company has 10,564 employees and is headquartered in São Paulo.

Company facts

Industry
Drug Manufacturers - Specialty & Generic
Country
Brazil
Headquarters
Av. Magalhães de Castro, 4800, 05676-120, São Paulo
Employees
10,564
Chief executive
Breno Pires de Oliveira
Founded
1999
Fiscal year
January - December
Listing
HYPE3 · B3
Indices
Ibovespa
Currency
BRL
ISIN
BRHYPEACNOR0

Hypera and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
HyperaHYPE3Brazil$2.58B10,56428.1%8.09
Genomma Lab InternacionalLAB/BMexico$776.89M1,80120.0%8.71
AlmirallALMSpain$2.45B2,1089.6%30.2
Siegfried HoldingSFZNSwitzerland$3.4B4,45416.7%16.7
Hims & Hers HealthHIMSUnited States$3.42B2,442-6.4%—
FagronFAGRBelgium$1.97B4,88014.3%19.5

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare Hypera with its competitors